New FDA Warning Added to Popular Weight Loss Drugs
Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration during general anesthesia or deep sedation. The affected drugs are liraglutide (Saxenda, Victoza), semaglutide (Ozempic, Rybelsus, Wegovy), and tirzepatide (Mounjaro, Zepbound).
Teenagers Are Taking New Weight-Loss Drugs, but the Science Is Far from Settled
Wegovy and similar weight-loss medications are becoming widely prescribed for teenagers with obesity, but little is known about their long-term effects
Novo’s New Obesity Drug Is Targeting the Most Dramatic Weight Loss Yet
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a red-hot market hinges on it.
Can new weight loss drugs fight the US obesity epidemic? Here's what to know
Obesity caused by a lifestyle of moving less and eating more is a prime factor contributing to Type 2 diabetes. Is the answer new weight loss drugs?
The end of a shortage of popular weight-loss drugs may mean many people lose access to them
Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a shortage of the brand-name drug has ended – which means compounding of the medicine must stop.
Microdosing Ozempic? Why some people are playing doctor with weight-loss drugs
As demand for popular weight-loss drugs like Wegovy and Zepbound skyrockets, patients are taking dosage amounts into their own hands.
A new weight loss drug could beat Ozempic's side effect problem
The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose pounds with fewer side effects than current anti-obesity medications on the market.
Concern over counterfeit versions of weight loss drugs like Ozempic
Experts say as drugs like Ozempic and Wegovy grow in popularity, it presents the chance for fake versions to make their way onto the market.
You Can Now Get Prescription Weight Loss Drugs Like Ozempic From An Online Telehealth Visit. But Is It Safe?
These drugs have also been in and out of shortage, making it tough to get your hands on Ozempic and similar medications—if you can afford it. Semaglutide medications like Ozempic and Wegovy are also reportedly getting closer to moving off the shortages list,
Nature2d
How ‘miracle’ weight-loss drugs will change the world
These are just some of the ways in which analysts forecast that the new wave of incredibly effective weight-loss ...
The Boston Globe20d
New weight loss drugs raise questions of access, costs
New, popular injectable weight loss drugs — GLP-1 drugs — are ... up from $125 million in 2022. Already in 2022, GLP-1 drugs accounted for 5 percent of pharmacy spending among people ...
UPI21d
Wegovy, other weight-loss drugs might help with alcoholism, opioid addiction
Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds. People taking this class of drugs ...
UPI News on MSN13d
Weight-loss surgeries decline 25% as GLP-1 drugs grow in popularity
As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim ...
CBS News21d
Weight loss drugs could help with alcohol and opioid addiction, new study shows
Diabetes and weight loss drugs like Mounjaro and Ozempic may also help patients suffering from addiction, according to a new study. In the study, published Thursday in the scientific journal ...
ABC News21d
Weight loss drugs like Ozempic may help reduce overdose risks: Study
A new study suggests that GLP-1 agonist medications like Ozempic, which are used for diabetes management and weight loss ... Over 75% of drug overdose deaths in 2022 involved opioids.
Forbes29d
Not Many Employers Cover GLP-1 Weight Loss Drugs
Despite the boom in popularity of expensive GLP-1 drugs to treat weight loss, fewer than one in ... [+] five large employers are covering such prescriptions, a new KFF analysis shows. In this ...